NCT01335373

Observational Program Neo-Penotran® Forte

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 13,024 (actual)
• Sponsor: Bayer · Industry
• Sex: Female
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Vaginitis is the most common gynecologic diagnosis in the primary care setting. In approximately 90 percent of affected women, this condition occurs secondary to bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis or mixed infection. Neo-Penotran Forte is registered for treatment of these most common vaginal infections. Efficacy and safety of this product is already established, and this observational study was designed to learn more about practical use of Neo-Penotran® Forte in real life setting.

Conditions

• Vaginal Candidiasis
• Bacterial Vaginosis
• Trichomonal Vaginitis

Interventions

Type	Name	Description
DRUG	Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)	Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.

Timeline

• Start date: 2010-10-01
• Primary completion: 2011-12-01
• Completion: 2015-04-01
• First posted: 2011-04-14
• Last updated: 2016-07-25

Locations

1 site across 1 country: Kazakhstan